Aducanumab, Amyloid Lowering, and Slowing of Alzheimer Disease
Stephen Salloway, Jeffrey L. Cummings
Abstract
Aducanumab (Aduhelm) was recently approved by the US Food and Drug Administration (FDA) for the treatment of Alzheimer disease (AD). The approval of aducanumab is controversial. We address why we support this decision and welcome the availability of aducanumab as an important therapy for patients with early AD.
Topics & Concepts
Food and drug administrationDiseaseMedicineAlzheimer's diseaseDrugAmyloid (mycology)Intensive care medicinePharmacologyInternal medicinePathologyAlzheimer's disease research and treatmentsCholinesterase and Neurodegenerative DiseasesDementia and Cognitive Impairment Research